Clarus Therapeutics and McGill University Announce Licensing Agreement to Develop and Commercialize Technology to Treat Coenzyme-Q10 Deficiencies

Published: 16 September 2021

Agreement to accelerate development of potential treatments for rare, endocrine, metabolic, and neurological conditions associated with primary and secondary ubiquinone deficiencies which belong to...

Back to top